"Tumor Microenvironment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
| Descriptor ID |
D059016
|
| MeSH Number(s) |
G04.366.500
|
| Concept/Terms |
Tumor Microenvironment- Tumor Microenvironment
- Microenvironment, Tumor
- Microenvironments, Tumor
- Tumor Microenvironments
Cancer Microenvironment- Cancer Microenvironment
- Cancer Microenvironments
- Microenvironment, Cancer
- Microenvironments, Cancer
|
Below are MeSH descriptors whose meaning is more general than "Tumor Microenvironment".
Below are MeSH descriptors whose meaning is more specific than "Tumor Microenvironment".
This graph shows the total number of publications written about "Tumor Microenvironment" by people in this website by year, and whether "Tumor Microenvironment" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 2 | 2 |
| 2011 | 2 | 3 | 5 |
| 2012 | 4 | 2 | 6 |
| 2013 | 0 | 5 | 5 |
| 2014 | 5 | 4 | 9 |
| 2015 | 4 | 9 | 13 |
| 2016 | 7 | 8 | 15 |
| 2017 | 6 | 17 | 23 |
| 2018 | 7 | 16 | 23 |
| 2019 | 14 | 18 | 32 |
| 2020 | 16 | 28 | 44 |
| 2021 | 12 | 29 | 41 |
| 2022 | 5 | 46 | 51 |
| 2023 | 6 | 44 | 50 |
| 2024 | 14 | 23 | 37 |
| 2025 | 14 | 31 | 45 |
| 2026 | 3 | 13 | 16 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Microenvironment" by people in Profiles.
-
Biomarker study of pembrolizumab in patients with advanced rare cancers. Cell Rep Med. 2026 Jun 16; 7(6):102827.
-
Targeting tumor-associated macrophage-induced IGF1/PI3K/Zic1 axis triggers SHH medulloblastoma regression and chemosensitization. Neuro Oncol. 2026 Jun 01; 28(6):1556-1570.
-
Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity. Med. 2026 Jul 10; 7(7):101149.
-
Pre-treatment of cabozantinib prior to hypofractionated radiotherapy increases immunomodulatory effects and tumor size reduction in a 4T1 breast cancer murine model. Sci Rep. 2026 May 16; 16(1).
-
Alprazolam Reduces Inflammatory Cytokine Production in Pancreatic Cancer-Associated Fibroblasts. Cancer Res Commun. 2026 May 01; 6(5):1048-1060.
-
Unbiased niche labeling maps immune-excluded niche in bone metastasis. Cell. 2026 May 28; 189(11):3287-3305.e25.
-
Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment. Nat Cancer. 2026 May; 7(5):723-739.
-
A 15-layer multi-omics analysis of gastric cancer ecotypes provides therapeutic insights. Cell Rep Med. 2026 May 19; 7(5):102756.
-
Chemotherapy-induced activation of caspase-1 and IL-1a release by cancer cells remotely skews myelopoiesis to drive pro tumorigenic systemic neutrophil-dominant inflammation. Nat Commun. 2026 Apr 20; 17(1).
-
NOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer. JCI Insight. 2026 Jun 08; 11(11).